The Pause Technologies Inc. Wins First Place in the HITLAB x Versalie™ Innovation Challenge

[Phoenix, AZ] — November 22nd, 2024 — The Pause Technologies Inc., the company behind the innovative menopause management platform thePause™, has been awarded first place in the prestigious HITLAB x Versalie™ Innovation Challenge. Selected from hundreds of innovative submissions, this accolade highlights thePause™’s mission to make menopause support accessible and personalized through their digital health platform. The company will receive a $25,000 prize to continue advancing its impactful work.Continue reading

AdvaMed Welcomes Bipartisan Senate Bill to Expedite Medicare Coverage of Breakthrough Medical Technologies, Diagnostic Tests

Washington, D.C. – AdvaMed, the Medtech Association, today welcomed introduction in the U.S. Senate of bipartisan legislation to expedite Medicare coverage of FDA-“breakthrough”-designated medical technologies and diagnostic tests. The legislation, the Ensuring Patient Access to Critical Breakthrough Products Act, introduced by Sen. Todd Young (R-IN) and Sen. Alex Padilla (D-CA), is similar to H.R. 1691, which the U.S. House of Representatives Ways and Means Committee passed on a bipartisan basis in June.  Continue reading

C-Path’s TRxA Announces $1 Million Award for Drug Development Project in Type 1 Diabetes

TUCSON, Ariz., November 19, 2024 — Critical Path Institute® (C-Path) today announced that its Translational Therapeutics Accelerator (TRxA) program, in partnership with The Leona M. and Harry B. Helmsley Charitable Trust, a new research grant aimed at developing a novel treatment for type 1 diabetes (T1D). This award is made through TRxA’s Bridging Research and Innovation in Drug Development Grants (BRIDGe) program, which is designed to support academic researchers in traversing the drug development valley of death and advancing new cutting-edge therapeutics from the lab to patients. Continue reading